News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
781,877 Results
Type
Article (55415)
Company Profile (497)
Press Release (725952)
Multimedia
Podcasts (143)
Webinars (23)
Section
Business (217761)
Career Advice (2889)
Deals (37457)
Drug Delivery (142)
Drug Development (87318)
Employer Resources (185)
FDA (17474)
Job Trends (16020)
News (370219)
Policy (35825)
Tag
2027 BioMidwest Elite (1)
2027 Biotech Bay Standard (2)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (3)
Academia (2942)
Academic (1)
Accelerated approval (37)
Adcomms (33)
Allergies (159)
Alliances (53351)
ALS (187)
Alzheimer's disease (1803)
Antibody-drug conjugate (ADC) (356)
Approvals (17680)
Artificial intelligence (591)
Autoimmune disease (176)
Automation (44)
Bankruptcy (391)
Best Places to Work (12295)
BIOSECURE Act (21)
Biosimilars (207)
Biotechnology (342)
Bladder cancer (169)
Brain cancer (64)
Breast cancer (683)
Cancer (5184)
Cardiovascular disease (462)
Career advice (2441)
Career pathing (41)
CAR-T (307)
CDC (59)
Celiac Disease (2)
Cell therapy (818)
Cervical cancer (38)
Clinical research (74173)
Collaboration (1886)
Company closure (4)
Compensation (1218)
Complete response letters (75)
COVID-19 (2944)
CRISPR (105)
C-suite (937)
Cystic fibrosis (153)
Data (6517)
Decentralized trials (2)
Denatured (44)
Depression (157)
Diabetes (536)
Diagnostics (7096)
Digital health (51)
Diversity (13)
Diversity, equity & inclusion (46)
Drug discovery (287)
Drug pricing (218)
Drug shortages (31)
Duchenne muscular dystrophy (252)
Earnings (93152)
Editorial (68)
Employer branding (23)
Employer resources (163)
Events (126303)
Executive appointments (1056)
FDA (20742)
Fibrodysplasia Ossificans Progressiva (7)
Friedreich's ataxia (12)
Frontotemporal dementia (25)
Funding (1585)
Gene editing (222)
Generative AI (52)
Gene therapy (675)
GLP-1 (1109)
Government (5193)
Grass and pollen (8)
Guidances (386)
Healthcare (20279)
HIV (68)
Huntington's disease (49)
IgA nephropathy (89)
Immunology and inflammation (299)
Immuno-oncology (71)
Indications (125)
Infectious disease (3248)
Inflammatory bowel disease (214)
Inflation Reduction Act (17)
Influenza (128)
Intellectual property (265)
Interviews (560)
IPO (17288)
IRA (59)
Job creations (4092)
Job search strategy (1985)
JPM (68)
Kidney cancer (19)
Labor market (87)
Layoffs (628)
Leadership (41)
Legal (8794)
Liver cancer (100)
Longevity (17)
Lung cancer (701)
Lymphoma (391)
Machine learning (44)
Management (63)
Manufacturing (863)
MASH (179)
Medical device (14500)
Medtech (14561)
Mergers & acquisitions (21250)
Metabolic disorders (1412)
mRNA (194)
Multiple sclerosis (173)
NASH (23)
Neurodegenerative disease (366)
Neuropsychiatric disorders (106)
Neuroscience (3172)
Neurotech (1)
NextGen: Class of 2026 (7261)
Non-profit (4956)
Now hiring (68)
Obesity (682)
Opinion (326)
Ovarian cancer (171)
Pain (220)
Pancreatic cancer (244)
Parkinson's disease (308)
Partnered (34)
Patents (534)
Patient recruitment (525)
Peanut (64)
People (64123)
Pharmaceutical (87)
Pharmacy benefit managers (32)
Phase 1 (23126)
Phase 2 (32519)
Phase 3 (24257)
Pipeline (5720)
Policy (338)
Postmarket research (2935)
Preclinical (9926)
Press Release (70)
Prostate cancer (262)
Psychedelics (59)
Radiopharmaceuticals (306)
Rare diseases (962)
Real estate (6483)
Recruiting (77)
Regulatory (26679)
Reports (54)
Research institute (2663)
Resumes & cover letters (459)
Rett syndrome (28)
RNA editing (21)
RSV (86)
Schizophrenia (164)
Series A (264)
Series B (204)
Service/supplier (14)
Sickle cell disease (109)
Special edition (27)
Spinal muscular atrophy (170)
Sponsored (45)
Startups (3960)
State (2)
Stomach cancer (21)
Supply chain (111)
Tariffs (95)
The Weekly (97)
Vaccines (1136)
Venture capital (100)
Weight loss (460)
Women's health (100)
Worklife (21)
Date
Today (206)
Last 7 days (786)
Last 30 days (2712)
Last 365 days (31613)
2026 (4588)
2025 (31852)
2024 (37131)
2023 (41909)
2022 (53246)
2021 (57908)
2020 (56648)
2019 (49890)
2018 (37733)
2017 (34716)
2016 (34539)
2015 (40639)
2014 (34676)
2013 (29991)
2012 (32010)
2011 (32485)
2010 (30743)
Location
Africa (934)
Alabama (93)
Alaska (7)
Arizona (330)
Arkansas (15)
Asia (44390)
Australia (8000)
California (11832)
Canada (3400)
China (1190)
Colorado (496)
Connecticut (514)
Delaware (350)
Europe (99603)
Florida (1771)
Georgia (374)
Hawaii (3)
Idaho (65)
Illinois (939)
India (74)
Indiana (546)
Iowa (24)
Japan (452)
Kansas (132)
Kentucky (44)
Louisiana (28)
Maine (72)
Maryland (1461)
Massachusetts (8582)
Michigan (345)
Minnesota (660)
Mississippi (6)
Missouri (141)
Montana (35)
Nebraska (28)
Nevada (127)
New Hampshire (86)
New Jersey (3139)
New Mexico (32)
New York (3119)
North Carolina (1620)
North Dakota (10)
Northern California (5762)
Ohio (351)
Oklahoma (21)
Oregon (46)
Pennsylvania (2372)
Puerto Rico (25)
Rhode Island (51)
South America (1305)
South Carolina (69)
South Dakota (1)
Southern California (4598)
Tennessee (182)
Texas (1825)
United States (42262)
Utah (358)
Vermont (1)
Virginia (283)
Washington D.C. (86)
Washington State (977)
West Virginia (4)
Wisconsin (123)
Wyoming (2)
781,877 Results for "c3j therapeutics formerly known as c3 jian inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Bausch Health Provides Update on RED-C Phase 3 Clinical Trials
January 26, 2026
·
3 min read
Press Releases
Agilent Receives FDA Approval for PD-L1 IHC 22C3 pharmDx in Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma (EOC)
February 11, 2026
·
3 min read
Press Releases
C4 Therapeutics Announces First Patient Dosed in Phase 2 MOMENTUM Trial of Cemsidomide, an Oral IKZF1/3 Degrader, in Combination with Dexamethasone for Relapsed/Refractory Multiple Myeloma
February 23, 2026
·
7 min read
Press Releases
Metagenomi Therapeutics, Inc. to Present at the 46th Annual TD Cowen Healthcare Conference
February 24, 2026
·
4 min read
Press Releases
Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - February 3, 2026
February 4, 2026
·
2 min read
Press Releases
Cypherpunk Technologies (formerly Leap Therapeutics) Reports Third Quarter 2025 Financial Results
November 13, 2025
·
16 min read
Press Releases
CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies
December 23, 2025
·
9 min read
Press Releases
The New England Journal of Medicine Publishes Positive Phase 3 VALIANT Results of EMPAVELI® (pegcetacoplan) for C3G and Primary IC-MPGN
December 4, 2025
·
13 min read
Press Releases
Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - December 3, 2025
December 4, 2025
·
1 min read
Press Releases
Enthorin Therapeutics Announces Initiation of Phase II Clinical Trial of MRM-3379 (Formerly ENT-3379) for Fragile X Syndrome by Licensing Partner Mirum Pharmaceuticals
January 12, 2026
·
2 min read
1 of 78,188
Next
